TYRA Stock Analysis: Buy, Sell, or Hold?
TYRA - Tyra Biosciences, Inc. Common Stock
$32.67
-0.08 (-0.24%)
▼
5d:
+5.87%
30d:
+28.52%
90d:
-7.35%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
30d
Smart Money Accumulation
None View Scanner →
Strength: 3.1/10
Get Alerted When TYRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TYRA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TYRA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TYRA is currently trading at $32.67, which is considered extended relative to its 30-day fair value range of $27.22 to $31.69.
Technical Outlook: Technically, TYRA is in a downtrend. The price is approaching resistance at $33.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TYRA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $51.97 (+59.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TYRA is in a downtrend. The price is approaching resistance at $33.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TYRA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $51.97 (+59.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$27.22 -
$31.69
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.1% below Wall St target ($51.97)
Trading Range Analysis
30-Day Trading Range
$27.22 -
$31.69
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$29.27
Resistance Level
$33.27
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.59
Wall Street Target
$51.97
(+59.1%)
Share & Embed Analysis
Last updated: July 13, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TYRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilla Kaplan
SELL
14295 shares
2026-03-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
